Epitan and pSivida complete sustained-release study
Wednesday, 18 May, 2005
A proof of concept study by Melbourne's Epitan (ASX:EPT) and nanotechnology company pSivida (ASX:PSD) has found that pSivida's BioSilicon technology can be used in a liquid-based sustained-release formulation of Epitan's tanning drug Melanotan.
The in-vivo study was conducted at the Institute of Medical and Veterinary Science in Adelaide.
Melanotan had previously been delivered as a daily injection, requiring significantly higher quantities of the drug.
A full international patent filed by Epitan in February covers the collaboration work between the two companies.
"The pSivida technology is for practical purposes a liquid, so it can be administered with a much finer gauge needle," said Epitan's managing director Iain Kirkwood.
From here, the companies will be looking at developing a formulation that can be used in a human trial.
The solid implant will still be the first generation of Melanotan at this point in time, said Kirkwood. However, the collaboration could lead to a second-generation injectable Melanotan product.
"[The study] shows that a more user friendly technology has been shown to work with Melanotan. It is good for both of us." said Kirkwood.
In the future, consumers could conceivably have the choice of a solid implant or a liquid injection of Melanotan.
Kirkwood recently upped his holding in Epitan by 23,000 shares, worth AUD$10,200.
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
